Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2016 - 2025)

Ultragenyx Pharmaceutical has reported Free Cash Flow over the past 10 years, most recently at -$99.8 million for Q4 2025.

  • Quarterly Free Cash Flow fell 14.05% to -$99.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$471.0 million through Dec 2025, down 9.79% year-over-year, with the annual reading at -$471.0 million for FY2025, 9.79% down from the prior year.
  • Free Cash Flow was -$99.8 million for Q4 2025 at Ultragenyx Pharmaceutical, down from -$95.5 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$16.3 million in Q4 2021 and troughed at -$193.9 million in Q1 2024.
  • The 5-year median for Free Cash Flow is -$94.1 million (2022), against an average of -$108.8 million.
  • Year-over-year, Free Cash Flow skyrocketed 66.76% in 2021 and then plummeted 439.34% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$16.3 million in 2021, then plummeted by 439.34% to -$87.9 million in 2022, then increased by 2.78% to -$85.4 million in 2023, then dropped by 2.4% to -$87.5 million in 2024, then dropped by 14.05% to -$99.8 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Free Cash Flow are -$99.8 million (Q4 2025), -$95.5 million (Q3 2025), and -$108.0 million (Q2 2025).